MV Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.9K Buy
66
+2
+3% +$603 ﹤0.01% 457
2026
Q1
$21.2K Buy
64
+1
+2% +$340 ﹤0.01% 441
2025
Q4
$25.1K Sell
63
-1
-2% -$443 ﹤0.01% 412
2025
Q3
$29.2K Buy
64
+1
+2% +$407 ﹤0.01% 381
2025
Q2
$20.5K Buy
63
+3
+5% +$830 ﹤0.01% 440
2025
Q1
$16.2K Buy
60
+10
+20% +$2.57K ﹤0.01% 457
2024
Q4
$11.8K Buy
50
+10
+25% +$2.63K ﹤0.01% 499
2024
Q3
$11K Buy
40
+14
+54% +$3.65K ﹤0.01% 515
2024
Q2
$6.32K Buy
26
+21
+420% +$3.31K ﹤0.01% 578
2024
Q1
$748 Buy
5
+2
+67% +$334 ﹤0.01% 695
2023
Q4
$575 Buy
+3
New +$511 ﹤0.01% 678

Other funds holding ALNY

MV Capital Management's ALNY Position: Q2 2026 in Review

MV Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 3.1% in Q2 2026, buying an estimated $603 and bringing the position to 66 shares worth $19.9K. The position accounts for ﹤0.01% of the portfolio, ranked #457.

MV Capital Management first reported a position in ALNY in Q4 2023 and has held it in 11 quarters since. The position peaked at $29.2K in Q3 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • MV Capital Management held 66 shares of Alnylam Pharmaceuticals worth $19.9K as of Q2 2026.
  • MV Capital Management bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
  • Alnylam Pharmaceuticals made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #457 holding.
  • MV Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • MV Capital Management's Alnylam Pharmaceuticals position peaked at $29.2K in Q3 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.